EXCEPTIONAL CASE

Iso-osmolar hyponatremia from polyethylene glycol

Bryan M. Tucker 1, James L. Pirkle2, Erinda Stefi3, David Sheikh-Hamad4 and Thomas DuBose5

1Section of Nephrology, Department of Medicine, Baylor College of Medicine, Houston, TX, USA, 2Section on Nephrology, Department of Internal Medicine, Wake Forest Baptist Medical Center, Winston-Salem, NC, USA, 3Section of Gastroenterology, Department of Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC USA, 4Department of Medicine, Section of Nephrology and Selzman Institute for Kidney Health, Baylor College of Medicine, Houston, TX, USA and 5Section on General Internal Medicine, Wake Forest School of Medicine, Winston-Salem, NC, USA

Correspondence to: Bryan Tucker; E-mail: bryan.tucker@bcm.edu

ABSTRACT

Understanding and applying pathophysiological concepts to patient care is an important skill for physicians in the clinical setting. Here, we present a case that demonstrates how the application of common physiological concepts relating to the widely accepted hyponatremia algorithm led to an accurate diagnosis of hyponatremia. This case documents iso-osmolar hyponatremia caused by orally administered polyethylene glycol absorption in the gastrointestinal tract. Herein, we discuss the workup and differential diagnosis for iso-osmolar hyponatremia in juxtaposition with the pathophysiological mechanisms unique to this case. We discuss these pathophysiological mechanisms based on the patients’ laboratory data and responses to therapeutic interventions.

Keywords: hyperkalemia, hyponatremia, ileus, iso-osmolar, osmolality, polyethylene glycol, sarcoidosis

INTRODUCTION

Polyethylene glycol (PEG) 3350 is described as ‘a mixture of nonabsorbable, nonmetabolized polymers’ that when administered orally acts as a ‘pure osmotic agent’ in the gastrointestinal (GI) tract (based on the manufacturers’ clinical review application for over-the-counter use) [1]. The compound is a polymer of ethylene oxide with the formula: HOCH2(CH2OCH2)nCH2OH and is commonly used clinically as an osmotic laxative. The ‘n’ in the formula can vary from 4 to 136 units of ethylene oxide [2]. The number that is seen after its name represents the average molecular weight of PEG molecules in the solution. For example, PEG 3350 contains molecules averaging 3350 g/mol (3350 Da or 3.350 kDa). This agent was approved by the Federal Drug Administration in 1998 for adults with occasional constipation and in 2005, it was approved for over-the-counter use. This widespread use of PEG is also supported by the American Gastroenterology Association, where it is broadly recommended as a first-line agent for constipation [3]. Although there was initial concern that this compound might be absorbed into the bloodstream producing systemic effects [4], this possibility has since been assumed to represent only a theoretical risk. We describe a case of iso-osmolar hyponatremia due to PEG absorption into the systemic circulation and discuss the workup, physiology and risk factors associated with the subsequent and unique downstream consequences. In this review, the abbreviation PEG will refer to PEG 3350 packaged without electrolytes, and.
Complete blood count

| Admission | Day 10 (consult day) |
|-----------|----------------------|
| WBC 13.2 x 10^9/L, Hgb 11.2 g/L, Plt 485 x 10^9/L | WBC 11.2 x 10^9/L, Hgb 11.6 g/L, Plt 512 x 10^9/L |

Basic metabolic panel

| Admission | Day 10 (consult day) |
|-----------|----------------------|
| Na 131 mmol/L, K 4.9 mmol/L, Cl 97 mmol/L, TCO2 23, BUN 20 mg/dl, Cr 0.96 mg/dl, glucose 137 mg/dl, Ca 8.6 mg/dl | Na 123 mmol/L, K 5.5 mmol/L, Cl 92 mmol/L, TCO2 22 mmol/L, BUN 20 mg/dl, Cr 1.0 mg/dl, glucose 88 mg/dl |

Other laboratory results

- Cortisol 18.2 mcg/dl, magnesium 1.4 mg/dl, phosphorus 4.4 mg/dl, alkaline phosphatase 377 mosm/kg H2O, blood Na measured using direct electrode 127.9, blood K measured using direct electrode 5.45 mmol/l, albumin 3.1 g/L, uric acid 3.9 mg/dl

Urine analysis

- Urinalysis: pH 6.5, specific gravity 1.020, WBC 0-5, RBC 0-3
- Urine sediment: Many large macrophage-like vacuolated renal tubular epithelial cells, unknown polarizing crystals, no casts
- Urine Na 150 mmol/L, urine K 38.1 mmol/L, urine Cl 68 mmol/L, urine Cr 121 mg/dl, osmolality (urine) 525 mosm/kg H2O → 787 mosm/kg H2O

**FIGURE 1**: Patient’s labs, urine sediment and timeline. (A) Patient’s laboratory results during inpatient admission. (B) Photomicrograph of patient’s urinary sediment examination, unpolarized. (C) Patients hospitalization during the first 13 days (x-axis) demonstrating the relationship between patient’s sodium, potassium and creatinine as they relate to PEG dose (thin red arrows = 17 g PEG dose; thick red arrows = 34 g PEG dose). Both a temporal and dose-dependent relationship is reliably seen; sodium decreases and potassium increases after each PEG dose. When PEG is discontinued, the electrolyte abnormalities and creatinine fluctuations also resolved. WBC, white blood cells; Hgb, hemoglobin; Plt, platelets; Na, sodium; K, potassium; Cl, chloride; TCO2, total carbon dioxide; Cr, creatinine; Ca, calcium; RBC, red blood cells.
if another compound or brand is discussed it will be labeled appropriately, as the size influences its pharmacokinetics.

**CASE PRESENTATION**

A 69-year-old, 72 kg man with advanced pulmonary sarcoidosis presented to the emergency department with increasing shortness of breath. Past medical history included active and advanced pulmonary sarcoidosis and a subtotal colectomy due to a concerning polyp. Patient denied tobacco, alcohol or illicit drug use and had no known drug allergies. On exam, the patient had conversational dyspnea, course crackles greater in the mid and upper lung fields, his heart had a regular rhythm although tachycardia was present, his abdomen was soft and non-tender and no lower extremity edema was present. Laboratory data (Figure 1A) demonstrate mild hyponatremia on admission. The patient was diagnosed with pneumonia and broad-spectrum antibiotics were started. Two days later, the patient developed an ileus and consultation by General Surgery recommended medical management with PEG. This treatment continued for 2 days but without a bowel movement. Accordingly, the dose of PEG was increased to 34 g twice daily from 17 g twice daily. Apart from the antibiotics, the patient’s shortness of breath was treated additionally with furosemide in the early hospital course. Subsequent laboratory data, 10 days into the hospitalization, revealed worsening hyponatremia and hyperkalemia; nephrology was consulted. An outline of the patient’s timeline of results is presented in Figure 1C along with input and output information (Supplementary data, Table S1).

**WORKUP AND DISCUSSION**

When a patient presents with hyponatremia, the expectation of a low-serum osmolality needs to be confirmed with the actual measurement of serum osmolality. A widely accepted formula for the calculation of the serum osmolality is serum osmolality (mOsm/kg H2O) = serum sodium (Na⁺ (mmol/L)) × 2 + serum blood urea nitrogen (mg/dL) × 0.8 + serum glucose (mg/dL)/18. After calculating the expected serum osmolality and measuring the actual serum osmolality, the osmolar gap can be estimated by subtracting the calculated value from the measured value. An osmolar gap of <10 mOsm/kg H2O is considered normal. In this case, the patient had a calculated serum osmolality of 258 mOsm/kg H2O and a measured osmolality of 277 mOsm/kg H2O on Day 10, yielding an osmolar gap of 19 mOsm/kg H2O (elevated).

Iso-osmolar or hyperosmolar hyponatremia is caused by the addition of an ‘effective solute’ (e.g. glucose, mannitol or sucrose) to the serum. The term ‘effective’ refers to the ability of the compound to pull water across a biological membrane, also called osmosis, and these effective solutes can be differentiated from ‘ineffective solutes’ such as alcohol and urea. Once iso-osmolar hyponatremia and an osmolar gap were diagnosed in this case, we immediately began searching for potential effective solutes that might be present in the serum. The most plausible substance was PEG (see below). Apart from the biochemical plausibility, this diagnosis is further supported by the temporal and dose-dependent correlation of the laboratory results, and the direct correlation between PEG initiation and discontinuation and changes in the serum sodium and potassium for two separate time periods of its use without change or adjustment of any other medications (Figure 1C). Excessively high concentrations of PEG in the GI tract can be absorbed when contact time is prolonged, as in this case where an ileus was also present along with active sarcoidosis further increasing small intestine permeability.

The effectiveness of PEG as a laxative is dependent on its ability to pull water into the lumen of the colon [5]. If absorbed systemically in significant amounts, its strong osmotic pressure will persist as PEG enters the intravascular compartment [6–9]. Based on our patient’s clinical presentation of hyponatremia and an osmolar gap, a dilutional hyponatremia was present, and in the absence of hyperglycemia and other potential causes of an osmotic gap, such as mannitol, radiological contrast agents or alcohols, we reasoned that PEG was the cause of the hyponatremia and now speculate on the pathophysiological events occurring in our patient (Figure 2).

Enteral PEG absorption commonly occurs, although the small fraction of the ingested dose that is absorbed is not characteristically clinically significant. Most of the PEG absorption occurs in the jejunum and ileum, where molecules ranging from 60 to 40 000 Da show an inverse correlation between their size and degree of absorption [10–12]. The degree of absorption or intestinal permeability depends on many variables; including
transit time, mucosal surface area, contact time and transfer, mesenteric blood/lymphatic flow and kidney function. The major factors increasing intestinal permeability in our patient include ileus and sarcoidosis (interferon-c and tumor necrosis factor-a) [13, 14]. The absence of intestinal motility results in the progressive accumulation of intraluminal PEG, and in the face of an inflammatory (and infectious) state augmenting intestinal permeability, produce a favorable environment for the absorption of PEG (Figure 2A).

Upon entering the blood, most of PEG’s clearance occurs within 24 h via renal filtration [15]. As an effective osmole, PEG can shift water into the vascular space, diluting the serum sodium concentration, resulting in hyponatremia [Figure 2B(b1)].

Several reports of PEG administration and hyponatremia have been published, as presented in Table 1. The prevalence of hyponatremia is reported at 7% in bowel prep patients [22]. The underlying mechanism of hyponatremia is commonly confined to the hypo-osmolar subtype and no previously reported case presenting with an osmolar gap exists in the literature (Table 1).

Large amounts of water movement can move potassium down its concentration gradient (intracellular to extracellular) resulting in hyperkalemia, a process known as solvent drag. In this case, occurrences of hyperkalemia mirrored those of hypokalemia resulting in hyperkalemia from solvent drag ultimately leading to hyperkalemia, the patient’s sarcoidosis was too advanced, and he chose to pursue hospice care after a month in the hospital. He died a few days later.

**SUPPLEMENTARY DATA**

Supplementary data are available at ckj online.

**CONFLICT OF INTEREST STATEMENT**

None declared.

**REFERENCES**

1. Buck KK. Clinical Review Polyethylene Glycol 3350 Over-the-Counter Application 2005. https://www.accessdata.fda.gov/
